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OBJECTIVES: Limited information is available concerning the post-treatment neutrophil-lymphocyte ratio in
critical limb ischemia patients who receive conservative therapy. Accordingly, this study was designed to
evaluate the predictive value of the post-treatment neutrophil-lymphocyte ratio in critical limb ischemia
patients without surgery.
METHOD: From January 2009 to January 2011, critical limb ischemia patients were admitted to a vascular center.
The demographic data, patient histories, comorbidities and risk factors were documented, and the differential
cell count was determined at admission and seven days later after conservative therapy. The cutoff value of the
post-treatment neutrophil-lymphocyte ratio was determined by an ROC curve. Patients were divided into
groups A and B according to the cutoff value. Amputation-free survival was compared between groups.
Univariate and multivariate analyses were used to identify independent risk factors.
RESULT: A total of 172 patients were identified with a mean age 71.98±10.09 years; among them, 122 were
male. A value of 3.8 was identified as the cutoff value of the post-treatment neutrophil-lymphocyte ratio.
Groups A (post-treatment neutrophil-lymphocyte ratio Z3.8) and B (post-treatment neutrophil-lymphocyte
ratioo3.8) showed a significant difference in amputation-free survival (Po0.001). The 1-year, 2-year and 3-year
amputation-free survival rates were 79.6%, 55.6% and 46.3%, respectively, in group A; however, in group B,
these values were 89.7%, 79.3% and 75.9%, respectively. The post-treatment neutrophil-lymphocyte ratio was
identified as an independent predictive factor for amputation in critical limb ischemia patients (Po0.001).
CONCLUSION: The post-treatment neutrophil-lymphocyte ratio is an independent predictive factor for
amputation in critical limb ischemia patients. Patients with a post-treatment neutrophil-lymphocyte
ratio Z3.8 are likely to suffer from amputation; amputation-free survival usually occurs in patients with a
post-treatment neutrophil-lymphocyte ratio o3.8.
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’ INTRODUCTION
Critical limb ischemia (CLI) is a widespread disease in China,
especially in older people. Although statistics are lacking for the
Chinese population, according to epidemiological research of
other countries (1), more than 5 million Chinese indivi-
duals are estimated to suffer from CLI. Due to long-term
chronic ischemia, the end-point for CLI patients is usually
amputation. Therefore, a method of identifying CLI
patients with a high risk for amputation and performing
risk stratification at an early time point is always the focus
of clinical practice.
CLI is an atherosclerotic disease that is usually associated
with a general inflammatory response. Based on previous
studies, C-reactive protein (CRP), platelet aggregation, and
the neutrophil to lymphocyte ratio (NLR) have been
indicated as effective predictive markers for CLI patients
(2). The NLR has universally been accepted as a predictiveDOI: 10.6061/clinics/2015(04)09
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index for stent patency (3,4), amputation-free survival (AFS)
(5), and mortality (6-8). However, these studies usually focus
on preoperative or postoperative NLR in CLI patients who
have undergone an operation or intervention. Little research
has been performed on CLI patients who receive conserva-
tive treatment. Furthermore, the NLR has been adopted for
prognosis evaluation in various medical fields including
hearing loss (9), peripheral artery disease (PAD) (10,11),
bladder cancer (12), prostatic hyperplasia (13), pancreatic
cancer (14,15), and colorectal cancer (16,17).
However, whether the post-treatment NLR (post-NLR) can
predict the prognosis in CLI patients is unclear. Therefore,
the present study was designed to evaluate the predictive
value of the post-NLR in CLI patients who receive con-
servative therapy.
’ METHODS
Patients and methods
The objective inclusion criteria for enrolled patients with a
diagnosis of CLI consisted of more than two weeks of foot
pain associated with an ankle-brachial index of 0.4 or less, an
ankle systolic pressure of 50 mm Hg or less, or a toe systolic
pressure of 30 mm Hg or less (Rutherford categories 4 and
5 (18). Patients with a) decisive evidence of acute limb
ischemia; b) clinical symptoms or signs of sepsis, any other
inflammation or a white blood cell (WBC) count 410*109/L;
c) poor data integrity; d) a previous surgery history; or e) any
diseases or drug that would affect the lymphocyte count,
such as lymphopenia, lymphemia, acute cardinal infraction
and corticosteroid use, were excluded from this study.
In this study, all of the enrolled patients who received
conservative therapy were not candidates for revasculariza-
tion due to poor general condition, loss of indication, severe
local infection or patient unwillingness.
At admission, the demographics (age, gender), history
(smoking, drug use), comorbidities and results of laboratory
tests (in particular, the neutrophil, lymphocyte, and WBC
counts) were recorded in a specific database by doctors and
nurses. All enrolled patients received the same standardized
conservative therapy plan (antiplatelet, anticoagulation and
vasodilator drugs were given intravenously for approxi-
mately 7 days). The same blood tests were conducted 7 days
after admission.
NLR definition
The pre-treatment WBC and differential counts were
evaluated at admission before conservative therapy. The
post-treatment counts evaluated taken 7 days later after
conservative therapy was adopted. The NLR was calculated
by dividing the absolute neutrophil count by the absolute
lymphocyte count (19).
Follow-up after discharge
Discharged patients were followed via outpatient con-
sultation or telephone calls. Each patient received the
same unified follow-up form and was followed at the end
of the 1st, 3rd, 6th, and 12th month after discharge, then
annually thereafter. Telephone follow-up was performed at
the same intervals. In this study, the primary end-points
were amputation [above-the-knee amputation (AKA),
below-the-knee amputation (BKA) or Toe] or 36 months
after discharge.
Analysis method
Data analysis was performed with SPSS version 16 (SPSS Inc,
Chicago, IL). Categorical data and continuous variables were
compared with the chi-square test or Fisher's exact test and the
independent sample t-test, respectively. The incidence of
amputation was analyzed by the Kaplan-Meier method, and
the difference was compared with a log-rank test. Independent
risk factors were identified by multivariate Cox proportional
hazards regression analysis. The calculated P-values were
two-sided, and a P-value o0.05 was considered significant.
Ethics
The patients included in this study were recruited from the
Vascular Department of West China Hospital, Sichuan
University, between January 2009 and January 2011. The
study was approved by the Ethics Committee of West China
Hospital, Sichuan University.
’ RESULTS
Based on the exclusion criteria, 12 patients were excluded
from the final analysis due to a) determined evidence of
acute limb ischemia (n = 1); b) clinical symptoms or signs of
sepsis or any other inflammation or WBC counts4 10*109/L
(n = 6); c) poor data integrity (n = 3); or d) a history of
previous surgery (n = 2). A total of 172 patients were
included in the final outcome analysis.
Cutoff value of post-NLR identification
The analysis of the relationship between post-NLR
and AFS was conducted using tertiles of existing data (e.g.,
Post-NLR o3.4, Post-NLR 46.8 and Post-NLR between
3.4 and 6.8). This grouping method showed a significant
discrimination effect (P = 0.006, Figure 1).
The post-NLR appeared to have a significant influence on the
outcome in a continuous manner. The post-NLR appeared to be
negatively correlated with the outcome. An ROC curve was
used to identify the cutoff value, which is shown in Figure 2. In
the ROC analysis setting, amputation was set as the state
variable. The C-statistic (area under the curve) was 0.740. A
Figure 1 - Association between post-NLR and amputation-free
survival (P=0.006).
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post-NLR of 3.8 was selected as the cutoff value because it had
the maximum discriminative power (sensitivity 70.2%, specifi-
city 71.7%). Seventy-four patients (43%) had a post-NLRZ3.8,
and 98 patients had a post-NLR o3.8.
Baseline characteristics
A total of 172 patients with mean age of 71.98±10.09 years
were included, and 70.9% (n= 122) of these patients were
male. The mean follow-up duration was 34.7 months (range
3.25 to 62.5 months). The 74 patients with a post-NLR Z3.8
were collectively called group A, and the 98 patients with a
post-NLR o3.8 were called group B. The mean ages in
groups A and B were 71.83±11.00 and 72.00±9.52,
respectively. The baseline characteristic comparison between
group A and group B is shown in Table 1. The incidence of
diabetes mellitus, the pre-NLR, the post-NLR, the monocyte
count, and the cholesterol level were significantly different
between the two groups.
Impact of the post-NLR on amputation
Overall, the AFS rates in group A (post-NLR Z3.8) and
group B (post-NLR o3.8) were 43.2% and 82.7%, respec-
tively. Furthermore, the 1-year, 2-year and 3-year incidence
rates of AFS in group A were 83.8%, 67.6% and 43.2%,
respectively. By contrast, the respective 1-year, 2-year
and 3-year AFS rates were 89.8%, 82.7% and 82.7% in group
B. Thus, 42 patients suffered from amputation during follow-
up in group A, whereas only 17 patients received amputa-
tions in group B (Po0.001). A detailed comparison of
amputation instances is shown in Table 2. Moreover, the
survival outcome showed a significant difference between
groups A and B (Po0.001), which is shown in Figure 3.
Independent risk factor identification
Risk factors for CLI patients, including diabetes mellitus,
pre-NLR, post-NLR, monocyte albumin and cholesterol
level, were included in the multivariate analysis (Cox
proportional hazards model). The analysis results showed
that the post-NLR and albumin were independent risk
factors of amputation (hazard ratios [95% confidence
interval]: 1.140 [1.086, 1.197] and 0.914 [0.856, 0.976],
respectively). These data are shown in Table 3.
Figure 2 - Power of diagnostic value (C-statistic is 0.740).
Table 1 - Baseline characteristics of 172 CLI patients
compared according to post-NLR.
Factor Group A
(post-NLR
X3.8)
Group B
(post-NLR
o3.8)
P-value
Gender (male/female) 50/24 72/26 NS
Smoking 40 60 NS
Hypertension 36 56 NS
Diabetes mellitus 8 22 0.046
Heart disease 18 26 NS
CAD 10 14 NS
Statin use 21 27 NS
Age 71.83±11.00 72.00±9.52 NS
Glucose 7.12±3.25 6.52±2.45 NS
Neutrophil count 5.42±2.52 5.29±2.19 NS
Lymphocyte count 1.48±0.49 1.40±0.60 NS
Pre-NLR 6.27±5.05 4.37±2.49 0.004
Post-NLR 7.57±4.46 2.20±0.99 o0.001
Monocyte 0.59±0.23 0.48±0.18 0.001
WBC 6.85±1.36 6.47±1.26 NS
Albumin 36.72±4.34 37.99±3.96 0.049
Potassium 3.88±0.49 3.90±0.49 NS
Creatinine 84.33±31.11 83.70±28.60 NS
HDL 1.11±0.38 1.17±0.39 NS
LDL 2.56±0.82 2.35±0.71 NS
TG 1.82±1.40 1.45±0.96 NS
Cholesterol 4.41±0.97 4.00±0.97 0.009
Social status NS
Bachelor or greater
education
12 8
Middle school
education
76 43
Primary school
education
18 15
Living condition NS
Nursing home 21 14
Private home 85 52
Fontaine grade NS
II 2 4
III 48 66
IV 24 28
CAD: coronary artery disease; Pre-NLR: pre-treatment neutrophil to
lymphocyte ratio; Post-NLR: post-treatment neutrophil to lymphocyte
ratio; WBC: white blood cell; HDL: high density lipoprotein; LDL: low
density lipoprotein; TG: triglyceride. *Po0.05 was considered a significant
difference; NS indicated no significance.
Table 2 - Amputation comparison between Groups A and B
Group A
(post-NLR X3.8)
Group B
(post-NLR o3.8)
P-value
Amputation/Total 42 17 o0.001
AKA 1 1 NS
BKA 12 5 0.016
Toe 29 11 o0.001
*AKA: above-knee amputation; BKA: below-knee amputation.
*Po0.05 was considered a significant different; NS indicated no significance.
275
CLINICS 2015;70(4):273-277 Neutrophil-lymphocyte ratio predicts amputation
Luo H et al.
’ DISCUSSION
The post-NLR was identified as an independent predictive
factor of amputation in CLI patients who did not undergo
surgery. CLI patients usually suffer from malnutrition (20)
due to sleeplessness and lack of appetite, leading to chronic
ischemic pain. Moreover, variable albumin is a crucial index
for evaluating a patient's nutritional condition, and hypo-
proteinemia is a risk factor for amputation in PAD (21,22). In
this study, albumin was identified as an independent
protective factor, which is in accordance with previous
studies.
With respect to previous studies, major lower limb
amputations (AKA or BKA) at 1 year occur in approximately
20% of untreated CLI patients (23,24). In this study, the
1-year amputation rate was 16.2% in group A (post-NLR
Z3.8) and 10.2% in group B (post-NLR o3.8). Therefore, no
significant difference in the final outcome was observed for
untreated CLI patients and patients who received conserva-
tive therapy. This result needs to be confirmed by a
systematic review or randomized controlled trial in the
future. However, this study suggests that CLI patients with a
higher post-NLR have a worse prognosis.
A risk-stratification model is an important clinical tool that
uses existing clinical data to predict a patient's prognosis and
provides a rational discrimination between risky and non-
risky patients. The NLR contains crucial information regard-
ing the patient's inflammatory condition. Moreover, the NLR
is different from other inflammation markers. It is an
inexpensive and readily available marker that is directly
calculated from the neutrophil and lymphocyte counts and
can easily be obtained from a complete blood cell test on
admission.
Furthermore, CLI is a form of chronic atherosclerosis, and
fibrosis progression is associated with the general immune-
inflammatory response. Repeated local inflammatory
responses involving the neutrophils and lymphocytes lead
to fibrosis, which aggravates ischemia. The NLR is an
effective systematic inflammatory marker that represents the
inflammatory condition. When severe ischemia occurs and
infection and immune disease are simultaneously excluded,
a systematic increase in the post-NLR could represent an
irreversible ischemic condition that may lead to an endpoint
event (e.g., amputation). The NLR predicts endpoint events
in other medical fields, including myocardial ischemia (25)
and severe sepsis (26).
In this study, all of the enrolled patients underwent
conservative therapy; however, compared with all CLI
patients over the same period of time, the proportion of
patients receiving conservative therapy was still low.
Previous studies have shown that revascularization proce-
dures (e.g., surgery and angioplasty/stenting) can produce a
better prognosis than conservative therapy (27-29). In terms
of patients who are suitable candidates for revascularization,
surgery, intervention or a hybrid procedure is still the
optimal choice.
Although this study is prospective with respect to patient
collection and discharge follow-up, selection bias cannot be
denied. Nearly all of the enrolled patients used antiplatelet
therapy, but only 48 subjects (27.9%) received statins. In
addition, the post-NLR could not be compared with other
inflammatory markers, such as C-reactive protein or the
erythrocyte sedimentation rate, because they are not routine
tests performed at admission. Moreover, isolated patients
with anemia and a hemoglobin level of less than 70 g/L
received transfusion therapy. This confounding factor was
not included in the analysis in this study.
The post-NLR is an effective marker for amputation in CLI
patients who do not undergo an operation. When the post-
NLR Z3.8, CLI patients are more likely to suffer from
amputation compared with patients with a post-NLR o3.8.
To avoid amputation and increase AFS, revascularization
procedures are still the optimal choice.
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